{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:12:23Z","timestamp":1778548343788,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["32003B _ 185111\/1"],"award-info":[{"award-number":["32003B _ 185111\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jpba.2022.114980","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T21:04:08Z","timestamp":1659387848000},"page":"114980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Development and validation of an LC-MS\/MS method for the quantification of mescaline and major metabolites in human plasma"],"prefix":"10.1016","volume":"220","author":[{"given":"Jan","family":"Thomann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Ley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Klaiber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias E.","family":"Liechti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urs","family":"Duthaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jpba.2022.114980_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.3109\/15563650903586745","article-title":"Peyote and mescaline exposures: a 12-year review of a statewide poison center database","volume":"48","author":"Carstairs","year":"2010","journal-title":"Clin. Toxicol."},{"issue":"3","key":"10.1016\/j.jpba.2022.114980_bib2","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and pharmacodynamic aspects of peyote and mescaline: clinical and forensic repercussions","volume":"12","author":"Dinis-Oliveira","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"issue":"10","key":"10.1016\/j.jpba.2022.114980_bib3","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1021\/acschemneuro.8b00215","article-title":"Dark classics in chemical neuroscience: mescaline","volume":"9","author":"Cassels","year":"2018","journal-title":"ACS Chem. Neurosci."},{"issue":"1","key":"10.1016\/j.jpba.2022.114980_bib4","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jep.2005.04.022","article-title":"Prehistoric peyote use: alkaloid analysis and radiocarbon dating of archaeological specimens of Lophophora from Texas","volume":"101","author":"El-Seedi","year":"2005","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.jpba.2022.114980_bib5","series-title":"Abuse of magic mushroom, peyote cactus, LSD, khat, and volatiles, Critical Issues in Alcohol and Drugs of Abuse Testing","first-page":"477","author":"Dasgupta","year":"2019"},{"key":"10.1016\/j.jpba.2022.114980_bib6","unstructured":"International Narcotics Control Board, List of psychotropic substances under international control, (2020)."},{"issue":"11","key":"10.1016\/j.jpba.2022.114980_bib7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1176\/ajp.131.11.1247","article-title":"Peyote in the treatment of alcoholism among American Indians","volume":"131","author":"Albaugh","year":"1974","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jpba.2022.114980_bib8","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.neuropharm.2017.12.040","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.jpba.2022.114980_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09699260.2022.2001140","article-title":"The therapeutic potential of psychedelic substances in hospice and palliative care","volume":"30","author":"Garcia","year":"2022","journal-title":"Prog. Palliat. Care"},{"issue":"3","key":"10.1016\/j.jpba.2022.114980_bib10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","article-title":"Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects","volume":"46","author":"Holze","year":"2021","journal-title":"Neuropsychopharmacology"},{"issue":"17","key":"10.1016\/j.jpba.2022.114980_bib11","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1097\/00001756-199812010-00024","article-title":"Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action","volume":"9","author":"Vollenweider","year":"1998","journal-title":"Neuroreport"},{"key":"10.1016\/j.jpba.2022.114980_bib12","article-title":"Receptor interaction profiles of 4-alkoxy-3,5-dimethoxy-phenethylamines (mescaline derivatives) and related amphetamines","volume":"12","author":"Kolaczynska","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"8","key":"10.1016\/j.jpba.2022.114980_bib13","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.euroneuro.2016.05.001","article-title":"Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens","volume":"26","author":"Rickli","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.jpba.2022.114980_bib14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.pharmthera.2003.11.002","article-title":"Hallucinogens","volume":"101","author":"Nichols","year":"2004","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.jpba.2022.114980_bib15","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1038\/s41386-022-01297-2","article-title":"Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects","volume":"47","author":"Holze","year":"2022","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.jpba.2022.114980_bib16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/BF00427703","article-title":"Metabolic fate of mescaline in man","volume":"9","author":"Charalampous","year":"1966","journal-title":"Psychopharmacologia"},{"issue":"3","key":"10.1016\/j.jpba.2022.114980_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/0006-2952(66)90298-X","article-title":"Comparison of the metabolism of 3, 4-dimethoxyphenylethylamine and mescaline in humans","volume":"15","author":"Friedhoff","year":"1966","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.jpba.2022.114980_bib18","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1749-6632.1962.tb50099.x","article-title":"Methylation and demethylation in relation to the in vitro metabolism of mescaline","volume":"96","author":"Daly","year":"1962","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.jpba.2022.114980_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/jat\/32.3.227","article-title":"Development and clinical application of an LC-MS-MS method for mescaline in urine","volume":"32","author":"Bj\u00f6rnstad","year":"2008","journal-title":"J. Anal. Toxicol."},{"issue":"7","key":"10.1016\/j.jpba.2022.114980_bib20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1365\/s10337-008-0553-2","article-title":"LC-PAD determination of mescaline in cactus \u201cpeyote\u201d(Lophophora williamsii)","volume":"67","author":"Casado","year":"2008","journal-title":"Chromatographia"},{"issue":"1","key":"10.1016\/j.jpba.2022.114980_bib21","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1556-4029.2012.02249.x","article-title":"GC\u2010MS and GC\u2010MS\/MS in PCI mode determination of mescaline in peyote tea and in biological matrices","volume":"58","author":"Gambelunghe","year":"2013","journal-title":"J. Forensic Sci."},{"issue":"6","key":"10.1016\/j.jpba.2022.114980_bib22","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/FTD.0000000000000220","article-title":"Urine mescaline screening with a biochip array immunoassay and quantification by gas chromatography\u2013mass spectrometry","volume":"37","author":"Battal","year":"2015","journal-title":"Ther. Drug Monit."},{"issue":"1","key":"10.1016\/j.jpba.2022.114980_bib23","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/1556-4029.14134","article-title":"An efficient ambient ionization mass spectrometric approach to detection and quantification of the mescaline content of commonly abused cacti from the Echinopsis genus","volume":"65","author":"Longo","year":"2020","journal-title":"J. Forensic Sci."},{"key":"10.1016\/j.jpba.2022.114980_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123202","article-title":"Detection of mescaline in human hair samples by UPLC-MS\/MS: application to 19 authentic forensic cases","volume":"1195","author":"Yang","year":"2022","journal-title":"J. Chromatogr. B"},{"issue":"3","key":"10.1016\/j.jpba.2022.114980_bib25","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1093\/jat\/24.3.211","article-title":"GC-MS identification of sympathomimetic amine drugs in urine: rapid methodology applicable for emergency clinical toxicology","volume":"24","author":"Valentine","year":"2000","journal-title":"J. Anal. Toxicol."},{"issue":"6","key":"10.1016\/j.jpba.2022.114980_bib26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/jms.853","article-title":"Screening for and validated quantification of phenethylamine\u2010type designer drugs and mescaline in human blood plasma by gas chromatography\/mass spectrometry","volume":"40","author":"Habrdova","year":"2005","journal-title":"J. Mass Spectrom."},{"issue":"2","key":"10.1016\/j.jpba.2022.114980_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/jms.1132","article-title":"Detection and validated quantification of nine herbal phenalkylamines and methcathinone in human blood plasma by LC\u2010MS\/MS with electrospray ionization","volume":"42","author":"Beyer","year":"2007","journal-title":"J. Mass Spectrom."},{"issue":"11","key":"10.1016\/j.jpba.2022.114980_bib28","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/rcm.3010","article-title":"Simultaneous determination of psychotropic phenylalkylamine derivatives in human hair by gas chromatography\/mass spectrometry","volume":"21","author":"Kim","year":"2007","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpba.2022.114980_bib29","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jpba.2014.08.006","article-title":"Ultra-high-pressure liquid chromatography tandem mass spectrometry determination of hallucinogenic drugs in hair of psychedelic plants and mushrooms consumers","volume":"100","author":"Pichini","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/j.jpba.2022.114980_bib30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jat\/bkaa089","article-title":"Screening of 104 new psychoactive substances (NPS) and other drugs of abuse in oral fluid by LC\u2013MS-MS","volume":"44","author":"Francisco da Cunha","year":"2020","journal-title":"J. Anal. Toxicol."},{"issue":"1\u20132","key":"10.1016\/j.jpba.2022.114980_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0021-9673(92)80271-U","article-title":"Determination of psychotropic phenylalkylamine derivatives in biological matrices by high-performance liquid chromatography with photodiode-array detection","volume":"593","author":"Helmlin","year":"1992","journal-title":"J. Chromatogr."},{"issue":"4","key":"10.1016\/j.jpba.2022.114980_bib32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1021\/np50046a050","article-title":"Cactus alkaloids, LXI. Identification of mescaline and related compounds in eight additional species using TLC and MS\/MS","volume":"49","author":"Ma","year":"1986","journal-title":"J. Nat. Prod."},{"issue":"2","key":"10.1016\/j.jpba.2022.114980_bib33","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.aca.2010.07.011","article-title":"Micro-solid phase extraction coupled with high-performance liquid chromatography\u2013tandem mass spectrometry for the determination of stimulants, hallucinogens, ketamine and phencyclidine in oral fluids","volume":"675","author":"Sergi","year":"2010","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpba.2022.114980_bib34","unstructured":"U.S. Food and Drug Administration, Bioanalytical method validation guidance for industry, (2018)."},{"issue":"3","key":"10.1016\/j.jpba.2022.114980_bib35","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/chromsci\/bmr049","article-title":"Increasing the sensitivity of an LC\u2013MS method for screening material extracts for organic extractables via mobile phase optimization","volume":"50","author":"Hua","year":"2012","journal-title":"J. Chromatogr. Sci."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522004010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522004010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:37:01Z","timestamp":1778546221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522004010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":35,"alternative-id":["S0731708522004010"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.114980","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and validation of an LC-MS\/MS method for the quantification of mescaline and major metabolites in human plasma","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.114980","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"114980"}}